AnaptysBio Statistics
AnaptysBio (AN6) Stock Statistics & Valuation Metrics
Total Valuation
AnaptysBio has a market cap or net worth of EUR 1.25B. The enterprise value is EUR 1.87B.
- Market Cap
- EUR 1.25B
- Enterprise Value
- EUR 1.87B
Share Statistics
AnaptysBio has 29,729,847 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 29,729,847
- Owned by Insiders
- 2.26%
- Owned by Institutions
- 43.37%
Financial Efficiency
AnaptysBio’s return on equity (ROE) is -0.36 and return on invested capital (ROIC) is 14.61%.
- Return on Equity (ROE)
- -0.36
- Return on Assets (ROA)
- -0.04
- Return on Invested Capital (ROIC)
- 14.61%
- Return on Capital Employed (ROCE)
- 0.15
- Revenue Per Employee
- 2.26M
- Profits Per Employee
- -127.23K
- Employee Count
- 104
- Asset Turnover
- 0.64
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of AnaptysBio is 7.27. AnaptysBio’s PEG ratio is -0.00.
- PE Ratio
- 7.27
- PS Ratio
- 7.18
- PB Ratio
- 66.30
- Price to FCF
- 38.31
- Price to Operating Cash Flow
- 38.46
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, AnaptysBio had revenue of 234.60M and earned -13.23M in profits. Earnings per share was -0.46.
- Revenue
- 234.60M
- Gross Profit
- 232.18M
- Operating Income
- 47.90M
- Pretax Income
- -13.07M
- Net Income
- -13.23M
- EBITDA
- 69.25M
- Earnings Per Share (EPS)
- -0.46
Cash Flow
In the last 12 months, operating cash flow was 35.89M and capital expenditures -1,000, giving a free cash flow of 35.89M billion.
- Operating Cash Flow
- 35.89M
- Free Cash Flow
- 35.89M
- Free Cash Flow per Share
- 1.20
Dividends & Yields
AnaptysBio pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 2.60%
- Earnings Yield
- 13.36%
Stock Price Statistics
- Beta
- 0.43
- 52-Week Price Change
- 51.09%
- 50-Day Moving Average
- 44.21
- 200-Day Moving Average
- 44.40
- Relative Strength Index (RSI)
- 49.69
- Average Volume (3m)
- 154
Important Dates
AnaptysBio upcoming earnings date is ―, TBA (Confirmed).
- Last Earnings Date
- Nov 12, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
AnaptysBio as a current ratio of 9.07, with Debt / Equity ratio of 37.93%
- Current Ratio
- 9.07
- Quick Ratio
- 9.07
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- -3.24
- Interest Coverage Ratio
- 0.60
Taxes
In the past 12 months, AnaptysBio has paid 164.00K in taxes.
- Income Tax
- 164.00K
- Effective Tax Rate
- -0.01
Enterprise Valuation
AnaptysBio EV to EBITDA ratio is 16.40, with an EV/FCF ratio of 35.10.
- EV to Sales
- 6.58
- EV to EBITDA
- 16.40
- EV to Free Cash Flow
- 35.10
- EV to Operating Cash Flow
- 35.10
Balance Sheet
AnaptysBio has EUR 152.99M in cash and marketable securities with EUR 12.57M in debt, giving a net cash position of EUR 140.43M billion.
- Cash & Marketable Securities
- EUR 152.99M
- Total Debt
- EUR 12.57M
- Net Cash
- EUR 140.43M
- Net Cash Per Share
- EUR 4.72
- Tangible Book Value Per Share
- EUR 0.70
Margins
Gross margin is 143.68%, with operating margin of 34.62%, and net profit margin of 96.30%.
- Gross Margin
- 143.68%
- Operating Margin
- 34.62%
- Pretax Margin
- -2.12%
- Net Profit Margin
- 96.30%
- EBITDA Margin
- 40.10%
- EBIT Margin
- 39.46%
Analyst Forecast
The average price target for AnaptysBio is EUR 72.31, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 72.31
- Price Target Upside
- 68.53% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 7
- Revenue Growth Forecast
- 8.60%
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 8
- AI Score
- ―
